Background-Ventricular arrhythmias remain a lethal complication of acute coronary syndromes (ACS). However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in contemporary non-ST-segment-elevation (NSTE) ACS populations are not well described. Methods and Results-We examined the incidence of VT/VF and subsequent survival among 9211 patients enrolled in the Early Glycoprotein IIb/IIIa Inhibition in NSTE ACS (EARLY ACS) trial. The cumulative incidence of VT/VF was 1.5% (nϭ141); 0.6% (nϭ55) had VT/VF Յ48 hours after enrollment, and 0.9% (nϭ86) had VT/VF Ͼ48 hours after enrollment. Patients with VT/VF more frequently had prior heart failure, an ejection fraction Ͻ30%, and triple-vessel coronary artery disease. Predictors of sustained VT/VF were similar regardless of the timing of VT/VF (Յ48 versus Ͼ48 hours). Patients with VT/VF Յ48 hours after enrollment had higher 30-day mortality than those who did not have VT/VF Յ48 hours (13.0% versus 2.2%; adjusted odds ratio, 6.73; 95% confidence interval, 2.68 -16.9). The increased risk of death associated with VT/VF Յ48 hours persisted at 1 year. The risk of mortality, relative to patients without VT/VF, was greater for patients with VT/VF Ͼ48 hours (hazard ratio, 20.70; 95% confidence interval, 15.39 -27.85) than for those with earlier VT/VF (hazard ratio, 7.45; 95% confidence interval, 4.60 -12.08; Pϭ0.0003). The frequency of arrhythmic death was higher in patients with VT/VF than in those without VT/VF (26.4% versus 6.9%).
survivors with a low left ventricular ejection fraction failed to show improved survival with implantable cardioverterdefibrillator therapy. 8, 9 Conventional wisdom and some observational studies suggest that sustained VT/VF early in the setting of ACS is due to reversible ischemia and that these patients are at low risk for death in follow-up if they are revascularized. 4, 10 However, long-term prognosis is not well described in these secondary prevention patients, particularly in those with VT/VF within 48 hours of an NSTE ACS. 7, 10 The objective of our analysis was to identify the frequency and timing of sustained VT/VF in NSTE ACS patients enrolled in the Early Glycoprotein IIb/IIIa Inhibition in NSTE ACS (EARLY ACS) trial, a contemporary NSTE ACS population. Furthermore, this analysis will ascertain whether patients with early sustained VT/VF after NSTE ACS are at increased risk for arrhythmic and all-cause mortality.
Methods
The details of the EARLY ACS trial have been published previously. 11 Briefly, EARLY ACS was a double-blind, randomized controlled trial of early versus delayed, provisional glycoprotein IIb/IIIa antagonist therapy with eptifibatide in patients with high-risk NSTE ACS. To be eligible, patients had to have 2 of 3 high-risk criteria: age Ն60 years, cardiac biomarker elevation (creatine kinase-MB, troponin I, or troponin T), or ST-segment depression or transient elevation. Patients between 50 and 59 years of age with known cardiovascular disease and an elevated creatine kinase-MB or troponin could also be enrolled. Patients were enrolled at 440 hospitals in 29 countries between May 2004 and August 2008. The final study cohort included 9406 patients, of whom 195 (2.1%) did not have a concurrent events assessment. Thus, 9211 patients had information available on in-hospital events, including VT/VF.
End-Point Definitions
The acute clinical event of interest in this analysis was the time to the first occurrence of sustained VT or VF before discharge from the index admission. Sustained VT/VF was defined as lasting Ͼ30 seconds and/or accompanied by hemodynamic compromise requiring electric defibrillation or the use of intravenous antiarrhythmic medications. The primary intermediate/long-term outcome of interest was all-cause mortality at 30 days and 1 year. Additionally, we examined cause-specific death at 30 days, including arrhythmic death. The occurrence of sustained VT/VF during hospitalization was collected on a standardized case report form as reported by the investigator. There was no central adjudication of this event. Death within 30 days of randomization was also collected on the case report form. Investigators were asked to provide cause of death for all reported deaths using a list given on the case report form. Cause of death was not centrally adjudicated. Arrhythmic death was defined as death that occurred suddenly and unexpectedly in a patient who was otherwise clinically stable. 4 Both witnessed and unwitnessed deaths (if the patient was known to be well and seen within 24 hours of death) were included.
Statistical Analysis
Baseline characteristics were summarized for groups with and without sustained VT/VF and for those with sustained VT/VF events by time of occurrence (Յ48 and Ͼ48 hours) through the use of percentages for categorical variables and medians with 25th and 75th percentiles for continuous variables.
Characteristics Associated With Sustained VT/VF
We used Cox proportional hazards regression modeling to identify baseline characteristics associated with the occurrence of all sustained VT/VF after randomization. Candidate variables included age, weight, sex, race, smoking status, diabetes mellitus, hypertension, family history of coronary artery disease, coronary artery disease, angina, MI, peripheral vascular disease, stroke, transient ischemic attack, percutaneous coronary intervention, coronary artery bypass grafting, blood pressure (systolic and diastolic), heart rate, Killip class at presentation, creatinine clearance, hemoglobin, hematocrit, and white blood cell count. Creatinine clearance was calculated with the Cockroft-Gault formula ([(140Ϫage)ϫweight in kilograms/serum creatinineϫ72]ϫ0.85 for female subjects). 12 Qualifying event variables included cardiac markers (creatine kinase-MB and troponin levels, positive or negative relative to the upper limit of normal for the site) and ECG changes (ST-segment depression Ͼ0.1 mV or transient ST-segment elevation Ͼ0.1 mV). Finally, the Thrombolysis in Myocardial Infarction (TIMI) unstable angina risk score classification at presentation was also considered. 13 The most appropriate functional form of each continuous variable was selected into the models. To prevent loss of observations during multivariable modeling, multiple imputations were performed for all covariates. Five imputed samples were generated with Markov chain Monte Carlo imputation methods with the PROC MI procedure in SAS version 9. We found that, with this sample size, using multiple imputations made little difference in the estimates compared with single imputation. One of the 5 imputed data sets was randomly selected to be used in calculating final results. Restricted cubic spline transformations were applied, and the model 2 values using a linear term only versus the spline transformation were compared to determine the deviation from the linearity assumption. A plot of the splinetransformed variable versus the log (hazard ratio) helped to elucidate an appropriate transformation to apply during the modeling process. A model with this final transformation was also compared with the restricted cubic spline model to ensure that nonlinearity was captured. Model development used stepwise selection to identify the predictive variables. Variables were selected for entry at a significance level of Pϭ0.10 and retained at Pϭ0.05. This process was bootstrapped 200 times. The factors that were chosen in at least 100 of these 200 samples were retained for the final model. The models were internally validated and calibration was assessed, also through the use of bootstrap techniques as described by Harrell. 14 The proportional hazards assumption was tested by the use of cumulative sums of Martingale residuals and was met for all covariates in the model.
Association of Sustained VT/VF With 30-Day and 1-Year Mortality
To assess the relationship of early sustained VT/VF (a postrandomization event) with 30-day mortality, a landmark approach was used. 15 A landmark period of 48 hours was created. There were 28 deaths within 48 hours of randomization; these patients were excluded from multivariable modeling. Of the 141 total sustained VT/VF events, 86 occurred beyond 48 hours after randomization. We evaluated the association between mortality after 48 hours and early sustained VT/VF events within 48 hours of randomization. The control group included patients who were alive at 48 hours who either did not experience VT/VF or had a VT/VF event Ͼ48 hours after randomization.
Logistic regression modeling was used to determine the association of sustained VT/VF within 48 hours with 30-day mortality. Adjusted models considered the following baseline characteristics that were associated with 30-day mortality in the EARLY ACS population in previous modeling: age, weight, Killip class, heart rate, systolic blood pressure, estimated creatinine clearance, ST-segment changes, prior MI, prior revascularization, prior peripheral vascular disease, white blood cell count, and elevated troponin.
Cox proportional hazards regression modeling with sustained VT/VF as a time-dependent covariate was used to assess the association of sustained VT/VF with 1-year mortality. By using sustained VT/VF as a time-dependent covariate, we were able to compare 1-year survival according to the timing of sustained VT/VF (Յ48 versus Ͼ48 hours). The 1-year survival model was constructed as an adjustment model. We included all covariates from the Global Registry of Acute Coronary Events (GRACE) and Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) 1-year mortality models. 16, 17 These variables included the same covariates as in the 30-day mortality model listed above, as well as sex, smoking status, diabetes mellitus, and prior heart failure.
In both the 30-day and 1-year models, we also adjusted for randomized treatment strategy (early versus delayed provisional eptifibatide) and prerandomization medications known to influence survival (angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, statin, and ␤-blockers). For the 30-day mortality model, because we used a 48-hour landmark, we also could adjust for revascularization (percutaneous or surgical) within 48 hours of randomization. To adjust for revascularization in the 1-year model, we used percutaneous coronary intervention or surgical revascularization as a time-dependent covariate. Finally, we also adjusted for left ventricular ejection fraction using a categorical variable (Ն0.50, 0.30 -0.49, Ͻ0.30) as recorded on the case report form. Interaction terms were included for the left ventricular ejection fraction category and sustained VT/VF. P for the interaction tests was based on the use of ejection fraction Ͼ50% as a reference category in the models.
In all analyses, a 2-tailed value of PϽ0.05 was considered statistically significant. Odds ratios with 95% confidence intervals (CIs) described the association of sustained VT/VF with 30-day mortality in both unadjusted and adjusted models. Hazard ratios with 95% CIs described the association of sustained VT/VF with 1-year mortality. No adjustments were made for multiple comparisons. All statistical analyses were performed with SAS statistical software version 9.1 (Cary, NC).
Results

Incidence of Sustained Ventricular Arrhythmias
Among the 9211 patients analyzed, 141 (1.5%) had sustained VT/VF after randomization. Seventy patients (0.8%) had sustained VT Ͼ30 seconds or requiring intervention for hemodynamic distress, and 84 (0.9%) had VF. Figure 1 shows the cumulative incidence of all sustained VT/VF events. The median time to the development of sustained VT/VF was 5 days (25th and 75th percentiles, 4 and 6 days). The frequency of sustained VT/VF Յ48 hours after randomization (nϭ55 of 9211, 0.6%) was similar to that Ͼ48 hours after randomization (nϭ86 of 9211, 0.9%).
Baseline Characteristics
Baseline characteristics of the full study population (nϭ9211) according to the occurrence of sustained VT/VF are shown in Table 1 . More patients with sustained VT/VF had a Killip class higher than I, an elevated troponin at baseline, and prior angina. The TIMI risk profile and frequency of prior MI were similar between groups. Patients with sustained VT/VF less often received upfront thienopyridine therapy and had lower estimated creatinine clearance at baseline. Time from hospitalization to randomization and time from randomization to catheterization were similar in those with and without sustained VT/VF. Patients with sustained VT/VF were more likely to have severe left ventricular dysfunction (22.4% versus 4.7% with ejection fraction Ͻ0.30), although 40% of all patients with sustained VT/VF had an ejection fraction Ͼ0.50.
In-Hospital Events After Randomization
Of the 6608 patients who underwent revascularization, 1.6% (nϭ108) had sustained VT/VF. The frequency of sustained VT/VF relative to revascularization was as follows: 12% (nϭ13 of 108) occurred before revascularization, 50% (nϭ54 of 108) occurred the same day as the revascularization procedure, and 38% (nϭ41 of 108) occurred after revascularization. Among those patients who survived to 30 days, the median time from admission to discharge was 10 days (25th and 75th percentiles, 5 and 14 days) versus 5 days (25th and 75th percentiles, 3 and 8 days) in those with and without sustained VT/VF, respectively. Table 2 shows the results of multivariable modeling for factors associated with the occurrence of sustained VT/VF. A calibration curve for the VT/VF model is shown in Figure 2 . There is reasonably close agreement between predicted and actual event rates. However, there is some underestimation and overestimation within the range of the observed data. Eight characteristics were identified as independently associated with sustained VT/VF. Increasing systolic blood pressure and estimated creatinine clearance were associated with a lower risk of sustained VT/VF, whereas higher white blood cell count, heart rate, and body weight were associated with greater risk of sustained VT/VF. Additionally, Killip class higher than I, elevated baseline troponin level, and prior angina were all associated with greater risk of sustained VT/VF. Investigating the time to any sustained VT/VF in a Cox model showed that there was no evidence of nonproportional hazards for any covariate, indicating that the predictors of sustained VT/VF were the same for both VT/VF within 48 hours and VT/VF after 48 hours. 
Predictive Model for Sustained VT/VF
Type of Sustained Ventricular Arrhythmia and 30-Day Mortality
Early Sustained VT/VF and 30-Day Mortality
The incidence of all-cause death from 48 hours to 30 days was greater in those with sustained VT/VF within 48 hours of randomization (nϭ6 of 46, 13.0%) compared with those without sustained VT/VF (nϭ202 of 9137, 2.2%; odds ratio, 6.84; 95% CI, 2.87-16.33). After adjustment for differences in baseline characteristics, randomized treatment, and medi- †WBC was fit by a linear relationship. This hazard ratio was created for 2ϫ10 9 /L-unit increases across the entire range of observed WBCs. ‡Creatinine clearance was fit by a linear relationship. This hazard ratio was created for 30-unit increases across the entire range of observed creatinine clearance.
§Weight was fit by a linear spline; there was no significant relationship for values Ͻ90 kg. This hazard ratio was created for 10-unit increases for weight Ͼ90 kg. ¶Heart rate was fit by a linear relationship. This hazard ratio was created for 20-unit increases across the entire range of observed heart rate. cations associated with 30-day mortality, the odds ratio was 6.73 (95% CI, 2.68 -16.90). The odds of death remained similar after additional adjustment for revascularization within 48 hours and left ventricular ejection fraction (Table  4 ). A left ventricular ejection fraction by VT/VF interaction term was not significant (Pϭ0.83).
Early Sustained VT/VF and Cause-Specific Death at 30 Days
In addition to all-cause death, we evaluated cause of death at 30 days among patients with sustained VT/VF within 48 hours and those without sustained VT/VF (Table 5 ). Heart failure death was similar between those with and without sustained VT/VF (28.3% versus 25.7%); however, arrhythmic death was more frequent in those with sustained VT/VF (26.4% versus 6.9%). Among those with sustained VT/VF, 22.6% died within 24 hours (nϭ32 of 141). When we excluded patients who died within 24 hours of sustained VT/VF, heart failure death was more frequent among patients with sustained VT/VF (nϭ9 of 21, 42.9%) than in those without sustained VT/VF (nϭ45 of 175, 25.7%).
Early and Late Sustained VT/VF and 1-Year Mortality
Using time-dependent analysis, we examined long-term survival after sustained VT/VF events Յ48 and Ͼ48 hours using patients with no sustained VT/VF as the reference group. Compared with patients without sustained VT/VF, patients with sustained VT/VF Ͼ48 hours had a higher risk of death at 1 year (hazard ratio, 20.70; 95% CI, 15.39 -27.85) than was observed for those with sustained VT/VF Յ48 hours (hazard ratio, 7.45; 95% CI, 4.60 -12.00; Pϭ0.0003 for the difference). These mortality risks persisted after further adjustment for revascularization and left ventricular ejection fraction ( Table 6 ). The left ventricular ejection fraction by VT/VF interaction terms were Pϭ0.07 for sustained VT/VF Յ48 hours and Pϭ0.08 for sustained VT/VF Ͼ48 hours ( Table 6 ). Sustained VT/VF events both Յ48 and Ͼ48 hours were associated with an increased hazard of death across all categories of left ventricular ejection fraction.
Discussion
There are 3 main findings in our analysis. First, in a contemporary, high-risk NSTE ACS population, the frequency of sustained VT/VF was lower than previously reported in ACS populations. Second, although infrequent, these events did not occur predominantly within 48 hours of presentation/enrollment. Finally, both early (Յ48 hours) and late (Ͼ48 hours) VT/VF events were associated with a markedly increased risk of death after discharge, even after adjustment for revascularization and left ventricular function.
Multiple studies from the thrombolytic era showed that the incidence of sustained VT/VF in the setting of STEMI was 5% to 10%. For example, among 13 921 patients in the Global Utilization of Streptokinase and TPA (Alteplase) for Occluded Coronary Arteries (GUSTO)-III trial, the incidence of sustained VT/VF was 7.5%. 3 In general, the incidence of sustained VT/VF complicating NSTE ACS has been lower. In a pooled analysis of 26 436 NSTE ACS patients enrolled in clinical trials in the 1990s, 2.1% developed sustained ventricular arrhythmias. 19 Recent advances and improvements in ACS care and outcomes raise the question of whether arrhythmic complications of NSTE ACS have changed over time or are different from those associated with STEMI. More contemporary estimates of the frequency of sustained ventricular arrhythmias in patients with NSTE ACS have been limited. In a study examining all patients undergoing percutaneous intervention for ACS (NSTE and STEMI) in the New York State registry, just over 5% of patients experienced sustained VT/VF. 20 In EARLY ACS, a population of contemporary high-risk NSTE ACS patients treated with an early invasive strategy and state-of-the-art medical therapy, we found that Ͻ1 in 60 patients developed sustained VT/VF. This frequency was lower than anticipated and may be explained in part by the selection of patients to undergo an early invasive strategy. On the other hand, EARLY ACS also targeted high-risk patients on the basis of age, elevated biomarkers, and ECG changes. Given the high-risk nature of the population, these findings may provide some reassurance that sustained ventricular arrhythmias are somewhat infrequent in the current era of NSTE ACS care. Alternatively, it is also possible that the enrollment strategy (median time from admission to enrollment Ͼ5 hours) may have decreased the likelihood of capturing early sustained VT/VF in the population.
In contrast with our data, prior studies, mostly in STEMI, suggested that sustained ventricular arrhythmias were most frequent within 24 to 48 hours after the onset of ischemia. For example, in the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial, 5 which enrolled Ͼ300 patients with STEMI, 90% of the observed sustained VT/VF events occurred within 48 hours of presentation. In APEX AMI, sustained VT/VF after 48 hours was uncommon and was associated with the absence of TIMI grade 3 flow and incomplete ST-segment resolution (Ͻ70%). In comparison, we found that, in a contemporary, high-risk NSTE ACS population, more than half (nϭ86 of 141, 60%) of all sustained VT/VF events occurred after 48 hours. Residual plaque instability associated with NSTE ACS (as opposed to complete vessel occlusion observed in STEMI) may contribute to the difference in the temporal relation of these arrhythmic events. However, in many institutions, telemetry and monitoring efforts are focused on the initial 48 hours. On the basis of these data, telemetry and monitoring should continue beyond 48 hours, particularly if the patient would otherwise be discharged without protective therapy such as an implantable cardioverter-defibrillator or wearable defibrillator. Because patients in EARLY ACS were randomized a median of 6 to 8 hours after presentation, it is possible that some early sustained VT/VF events were not captured; however, given the predominance of late VT/VF events, sustained VT/VF after 48 hours represents a significant proportion of NSTE ACS-associated VT/VF. Finally, these results are in line with recent findings from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome (MERLIN)-TIMI 36 trial in which nonsustained VT was most frequent 48 hours after hospital admission for NSTE ACS. 21 The American College of Cardiology/American Heart Association/Heart Rhythm Society 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities counsel, Patients experiencing cardiac arrest due to VF that occurs more than 48 hours after an MI may be at risk for recurrent cardiac arrest. It is recommended that such patients be evaluated and optimally treated for ischemia. If there is evidence that directly and clearly implicates ischemia immediately preceding the onset of VF without evidence of a prior MI, the primary therapy should be complete coronary revascularization. 7 However, in this NSTE ACS cohort with sustained ventricular arrhythmias, arrhythmic death was 3-fold greater in those with sustained VT/VF within 48 hours compared with those without sustained VT/VF. Alternatively, when we excluded deaths within 24 hours of sustained VT/VF, the frequency of heart failure death was greater than arrhythmic death. These data highlight the challenges surrounding appropriate secondary prevention of sudden death after NSTE ACS complicated by sustained ventricular arrhythmias. Whether revascularization and ␤-blockade provide adequate secondary prevention of arrhythmic death after NSTE ACS requires further study. Given the frequency of NSTE ACS across the globe and the gravity of sudden death, prospective clinical trials should be conducted to address this important clinical question. Potential therapies that should receive attention in clinical trials include novel risk stratification technologies, 22 existing pharmacotherapies (eg, aldosterone blockade), 23 wearable defibrillators, 24 and implantable defibrillators.
Limitations
Several important limitations must be considered. First, the primary event of interest (ie, sustained VT/VF) was a postrandomization event; therefore, it may be subject to the influence of temporal bias and confounding. 25 Accordingly, we used time-dependent variables and covariate adjustment VT/VF indicates ventricular tachycardia/ventricular fibrillation; HR, hazard ratio; CI, confidence interval; and LVEF, left ventricular ejection fraction. *P for interaction of sustained VT/VF by LVEF. P for the interaction tests was based on the use of LVEF Ն50% as the reference category.
in our models to address both temporal bias and confounding. When considering the adjustment for left ventricular ejection fraction, one should exercise a certain degree of caution when interpreting these data. Ejection fraction data were not collected in a standardized fashion and represent a postrandomization variable. Notably, EARLY ACS did not record implantable cardioverter-defibrillator status, an important intervention when mortality after ventricular arrhythmia is considered. Despite these limitations, our analysis has several noteworthy strengths. This study focuses on a contemporary, high-risk NSTE ACS population in the thienopyridine and invasive strategy era, a group in which both arrhythmias and the downstream outcomes after ventricular arrhythmias are not well studied. The study population was large and, given the carefully monitored environment of a clinical trial, not likely to have been affected by ascertainment or misclassification bias.
Conclusions
Sustained VT/VF occurred infrequently among patients with NSTE ACS. In contrast to prior experiences in STEMI, these events were not confined predominantly to the first 48 hours after NSTE ACS. Moreover, both early VT/VF and late sustained VT/VF were associated with a markedly increased risk of all-cause death at 30 days and 1 year after discharge despite revascularization. These data suggest that patients with NSTE ACS require monitoring beyond 48 hours and highlight the importance of investigating the efficacy of interventions such as the wearable defibrillator or an implantable cardioverter-defibrillator in preventing arrhythmic death in patients with early sustained VT/VF.
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